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Chronic myeloid leukemia (CML) is a clonal myaeloproliferative disorder characterized by masasive proliferation and accumulation of myeloid 
cells that differentiate normally.1,2 Almost all patients 
carry a specific translocation [t(9;22)(q34;q11.2)]3 and 
derivative [der(22)]- the Philadelphia chromosome 
(Ph)- that results in the juxtaposition of the DNA sea
quence from the BCR-ABL genes,4 and encodes a 210a
kilodalton dysregulated tyrosine kinase, which is neca
essary and sufficient for leukaemogenesis.5,6 Although 
this Ph chromosome is thought to be the initial event in 
CML, the acquisition of additional cytogenetic abnora
malities are likely responsible for disease progression.4 
The emergence of nonarandom chromosomal aba
normalities in addition to the Ph chromosome is a 
wellarecognized occurrence in CML and is referred 
to as clonal evolution.4 It is a marker of disease proa
gression and is thought to reflect the genetic instabila
ity of the highly proliferative CML progenitors.4 The 
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frequency of clonal evolution increases with advancing 
stage of CML, and is reported in about 30% of cases 
with accelerated phase7 and up to 80% in blast phase.8 
About 5% to 10%9 patients showed variant Ph transloa
cation by the involvement of one or more chromosome 
regions in addition to chromosomes 9 and 22.4,10 The 
clinical and prognostic significance of these cases have 
not been well described.8 Other chromosomal abnora
malities including an extra Ph chromosome, trisomy 
8, trisomy 19, and isochromosome 17q (with loss of 
p53)11 or 20q,12 which occur as the disease transforms 
to the aggressive phase. Regardless of the underlya
ing mechanisms, the net result of additional genetic 
abnormalities is the potential for a more malignant 
phenotype and, possibly, less dependence on BCR-
ABL for proliferation and survival.4,7 
The detection of these cytogenetic abnormalities 
may be important in stratifying patients into good and 
bad prognostic groups and to offer them appropriate 
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treatment options. Furthermore, until now there has 
been no data on the prevalence of these translocations 
from our region. Our objective was to determine the 
frequency and type of additional chromosomal aba
normalities other than (9; 22) (q34; q11) in patients 
with CML. To the best of our knowledge the impact of 
these abnormalities on the response to imatinib has not 
been studied from our region.
PATIENTS AND METHODS
This study was a descriptive, prospective analysis of 219 
patients with Phapositive CML (chronic, accelerated 
and blast phase according to WHO criteria),12 in all age 
groups and both sexes treated at Aga Khan University 
Hospital over a period extending from May 2001 to 
June 2007. The diagnosis of CML was based on characa
teristic peripheral blood smear and bone marrow exama
ination findings and was confirmed by presence of the 
Philadelphia chromosome on bone marrow cytogenetic 
studies or detection of the BCR/ABL translocation by 
polymerase chain reaction (PCR).
All 219 patients received hydroxyurea as an initial treata
ment, which also included 10 patients who were preatreata
ed with interferon. Imatinib mesylate was started at doses 
of 400 mg daily for the chronic phase and 600 mg daily for 
the accelerated and blast phase of the disease. We studied 
the cytogenetic response of this group. Cytogenetic analya
sis on cultured bone marrow aspirate samples antiacoagua
lated with heparin was performed using conventional trypa
sinagiemsa Gabanding technique, and described accorda
ing to the International System for Human Cytogenetic 
Nomenclature (ISCN). At least 20 metaphases were anaa
lyzed where possible. Cytogenetics was performed every 3 
to 6 months while on imatinib mesylate. Clonal cytogeneta
ic evolution was defined as gains in at least two metaphases 
or losses in at least three metaphases.
RESULTS
In 219 cases of Ph+ CML, we identified 34 (15.5%) 
cases that developed 51 additional chromosomal abnora
malities (Table 1). Prior to starting imatinib 5 cases of 
the 34 had a variant translocation, including two who 
were preatreated with interferon alfa. The rest of the 29 
cases acquired chromosomal abnormalities after starta
ing imatinib mesylate, which also included 8 cases that 
received interferon prior to imatinib.
Karyotype analysis 
We identified trisomy 8 as the commonest additional 
chromosomal abnormality, followed by variant Ph chroa
mosome and other random abnormalities (Figure 1). 
Trisomy 8 was detected as an isolated abnormality in nine 
cases, and it was noted in combination with other chromoa
somal aberrations in four cases. During a median followa
up of 18 months (range, 3a40 months) only one patient 
died in this group. Variants of Philadelphia chromosome 
were found in seven cases; five at diagnosis and two aca
quired later. Chromosomes 1, 3, and 5 were involved with 
one in each case and two cases had a chromosome 12 and 
17 translocation in addition to t(9;22). Median followaup 
of this group was 13 months (range, 2a36 months). Other 
abnormalities included monosomy 7 in combination with 
other aberrations (n=4), double Ph+ (n=7) and deletion 
Y (n=2) (Table 2). Overall, seven patients had more than 
one chromosomal abnormality. 
Table 1. Baseline characteristics of the 34 Ph+ CML patients with 
additional chromosomal abnormalities.
Characteristics Value (n)
Phase*
   Chronic 21
   Accelerated 10
   Blast 03
Gender
   Male 27
   Female 07
Age, median (years) 38
   Range 19-62
Prior interferon therapy 10
*defined according to WHO criteria.
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Figure 1. Frequency of various cytogenetic aberrations in 34 cases of Philadelphia-
positive chronic myeloid leukemia.
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Table 2. Philadelphia-positive chronic myeloid leukemia patients with additional chromosomal abnormalities.
No. Age Prior therapy Phase
Initial karyotype at
diagnosis
Time
of CE
(mo)
Karyotype with additional abnormalities Follow-up (mo)
1 24 HU CP 46XY, t(9;22)(20) 24 46XY, t(6;7), t(9;22) (17) 36
2 38 HU CP 46XY, t(9;22) (20) 18 47XY, +8, t(9;22) (10) 19
3 24 HU, IFN CP 46XY, t(9;22) (20) 10 46XY, -3, -7, t(9;22), 14p+, mar (8) 33
4 39 HU, IFN CP 46XY, t(9;22) (20) 8 47XY, +8(2), 45XY, -7, t(9;22), (9) 18
5 24 HU CP 46XY, t(9;22) (20) 11 47XY, +8(2) 20
6 35 HU, IFN CP 46XY, t(9;22) (20) 25 45XY, -7(9), 47XY, +8(5), 46XY, t(9;22) (22) 18
7 35 HU CP 46XX, t(9;22) (20) 11 47XX, t(9;22), +Ph (11) 36
8 27 HU, IFN CP 46XY, t(9;22) (20) 8 47XY, t(9;22), +Ph (05) 28
9 19 HU CP 46XY, t(9;22) (20) 27 47XY, +8(5) 19
10 34 HU, IFN CP 46XX, t(9;22) (20) 16 47XX, +8(12) 17
11 47 HU, IFN CP 46XY, t(3;9;22) (20) Diag 46XY, t(3;9;22) (20) 17
12 54 HU CP 46XY, t(9;22) (20) 21 47XY, +8(3), inv9, t(9 ;22) (12) 16
13 51 HU CP 46XX, t(9;22) (20) 5 46XX, t(9;22), inv9(15) 11
14 26 HU CP 46XY, t(9;22) (20) 11 45X-Y(6), 46XY, t(9;22) (20) 12
15 40 HU CP 46XY, t(9;22) (20) 6 47XY, t(9;22), +Ph (11) 12
16 37 HU, IFN CP 46XY, t(9;22) (20) 10 45X-Y(10) 38
17 37 HU CP 46XY, t(5;9;22) (20) Diag 46XY, t(5;9;22) (10) 6
18 40 HU CP 46XX, t(1;9;22) (20) Diag 46XX(16) 13
19 58 HU, IFN CP 46XY, t(9;12;22) (20) Diag 46XY, t(9;12;22), +Ph (2)/ 46XY, t(9;12;22) (15) 8
20 48 HU CP 46XY, t(9;22) (20) 8 47XY, t(9;22), +Ph (3) 14
21 62 HU CP 46XY, t(9;22) (20) 4 47XY, +8, t(9;22)(2) 3
22 30 HU AP 46XX, t(9;22) (20) 14 46XX, t(3;11), t(9;22), mar (10) 5
23 39 HU AP 46XY, t(9;22) (20) 12 46XY, t(9;22), del 20(20) 24
24 43 HU BC 46XY, t(9;22) (20) 24 46XY, t(1;2), t(9;22) (20) 43
25 37 HU AP 46XY, t(9;22) (20) 30 46XY, t(9;12;22) (11) 40
26 38 HU AP 46XY, t(9;22) (20) 22 47XY, +8 (14) 40
27 30 HU BC 46XY, t(9;22) (20) 20 47XY, +8, t(9;22), +Ph (10) 26
28 31 HU AP 46XY, t(9;22) (20) 20 47XY, +8 (3) 39
29 46 HU AP 46XY, t(9;22) (20) 9 47XY, +8 (7) 17
30 48 HU BC 46XY, t(9;17;22) (12) Diag 46XY(26) 13
31 44 HU AP 46XX, t(1;6), t(9;22) (20) 18 50XX, t(1;6), t(9;22), +8, +19, +21, +Ph (4) 15
32 24 HU, IFN AP 46XY, t(9;22) (20) 18 46XY, -3, -6, -7, t(9;22), 14p+, mar(14) 24
33 51 HU AP 46XY, t(9;22) (20) 6 46XY, t(9;17;22) (20) 16
34 45 HU, IFN AP 46XX, t(9;22) (20) 13 46XX, t(7;9), t(21;22) 36
CE: clonal evolution; HU: hydroxyurea; IFN: interferon-alfa; CP: chronic phase; AP: accelerated phase, BC: blast crisis; Diag: at diagnosis. 
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A complete cytogenetic response was observed in 5 of 
34 (14.7%) patients with additional cytogenetic abnora
malities. These included three cases with trisomy 8, who 
developed trisomy 8 in their Phanegative clone while on 
imatinib at 17, 39 and 40 months of followaup. The other 
three cases with trisomy 8 in a Ph negative clone by cona
ventional cytogenetics showed either signs of progressive 
disease or BCR/ABL positivity by FISH technique. Two 
patients that had a complete cytogenetic response with 
imatinib had a variant chromosome at the time of prea
sentation. At the median followaup of 19 months (range, 
3a43 months), 25 patients were alive, 8 had died with proa
gressive disease and 2 were lost to followaup.
DISCUSSION
In chronic phase CML, Philadelphia chromosome and 
BCR/ABL translocation is supposed to be the sole aca
quired genetic abnormality, so imatinib mesylate was 
assumed to be an ideal agent to block the defect, bea
cause it specifically inhibits the tyrosine kinase activity 
of the BCR/ABL protein.1,12 The acquisition of seconda
ary cytogenetic abnormalities may represent the changa
ing natural history of CML in an era of tyrosine kinase 
inhibitors, treatmentarelated effects or the manifestaa
tion of an underlying stem cell defect.13,14 Emergence 
of these cytogenetic abnormalities after interferon are 
a well known phenomenon in 50% to 60% cases; howa
ever, recently it has been recognized in patients receiva
ing imatinib as well.14,15 We found the overall frequency 
of additional chromosomal abnormalities in 34 (15.5%) 
cases, including Philadelphiaanegative clones in 6 cases. 
A similar incidence is observed in previous reports.14 
Of the 34 patients, 13 (38%) had trisomy 8, making it the 
most common chromosomal aberration in this group. 
This is in comparison with other studies conducted by 
O’Dwyer et al14 and Medina et al (32%).16 In the present 
study, variants of Ph chromosome, which involves t(9;22) 
in association with another chromosome, were seen in 
22% of cases, which is in contrast to Mohamed et al1 who 
reported variants in 8.6% of such cases. Chromosomes 1, 
3, 5 (n=1 in each), 12 (n=2) and 17 (n=2) were involved 
in addition to 9 and 22 in our study. The frequency of 
monosomy 7 and double Philadelphia is less in our sea
ries, however, and the incidence of the loss of the Y chroa
mosome is comparable to previous reports.17 The signifia
cance of the loss of the Y chromosome is unclear; it has 
been observed in healthy males. 
Random chromosomal abnormalities found in ina
dividual patients were loss of chromosome 3 and 6 in 
combination with monosomy 7 (n=4); del 20q (n=1), 
mar (n=3), all in combinations, 14p+ (n=2), and ina
version 9 (n=2). Other random abnormalities included 
t (1; 2), t (3; 11) in combination with mar, t(7; 9) in 
addition to t(21; 22), t(1; 6) and t(6; 7). Marker (mar) 
chromosome is a structurally abnormal chromosome in 
which no part can be identified; the clinical significance 
of this abnormality is not known.18 
Clonal evolution in interferonatreated patients is a 
well documented phenomenon and usually an indicaa
tion of disease progression,10 but recently this phenoma
enon has been recognized in patients treated with imaa
tinib mesylate.15 The extent to which these aberrations 
affect the prognosis and response to the therapy has 
only been studied in a small number of cases.10,15 
The mechanism of the emergence of these abnormal 
clones is unclear.14 The assumed causes of these additional 
chromosomal abnormalities include the inherent ability of 
a CML clone to transform into another malignant disora
der such as myelodysplasia,16 or there may be a multiastep 
leukemogenic pathogenesis apart from the BCR/ABL 
dependant mechanism, or it could be due to imatinib mea
sylate, which blocks the activity of BCR/ABL proteins so 
the remaining cells proliferate and develop random aba
normalities in a Philadelphiaa negative clone.14a16 Another 
possibility is the inherent instability of the CML clone 
that predisposes to other abnormalities.4 
In this series we identified a very small subset of paa
tients whose Ph+ clone remained sensitive to imatinib 
mesylate despite the presence of additional chromosoma
al abnormalities. A complete cytogenetic response was 
reported in 26% cases earlier;1 in contrast we observed 
this response in only 14% of patients. This supports a 
role for a monitoring algorithm that includes periodic 
bone marrow karyotyping of CML patients receiving 
imatinib mesylate to exclude the unrecognized coexa
isting myelodysplastic clones and/or clinical evolution 
in the absence of Ph+ cells. The early recognition of 
these abnormalities will lead to earlier and appropriate 
therapeutic intervention, which may include increasing 
the dosage of imatinib mesylate, combination therapy, 
other investigational agents and the choice and timing 
of allogeneic stem cell transplantation before progressa
ing to the accelerated or blast phase.13
In conclusion, acquisition of additional chromosoma
al abnormalities in CML is a well known phenomenon 
that can occur with tyrosine kinase inhibitors as well. 
There are some postulated mechanisms, but the exact 
pathogenesis and the underlying biology in acquisition 
of these abnormalities remains unclear, and requires 
molecular insights to clarify the details. Early identia
fication of these abnormalities may help in adapting a 
more appropriate therapeutic approach. However, large 
multiacenter studies are needed for further clarification 
of the clinical relevance.
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